Valuation: Caris Life Sciences, Inc.

Capitalization 4.74B 4.04B 3.71B 3.51B 6.5B 453B 6.56B 44.14B 17.19B 215B 17.78B 17.4B 747B P/E ratio 2026 *
133x
P/E ratio 2027 * 49.2x
Enterprise value 4.26B 3.63B 3.33B 3.15B 5.84B 407B 5.9B 39.66B 15.45B 193B 15.97B 15.64B 672B EV / Sales 2026 *
4.24x
EV / Sales 2027 * 3.34x
Free-Float
51.18%
Yield 2026 *
-
Yield 2027 * -
05-12 Caris Life Sciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM
05-12 Caris Life Sciences Insider Bought Shares Worth $501,426, According to a Recent SEC Filing MT
05-11 Caris Life Sciences Publishes Study Showing Whole Exome Measurement Of Tumor Mutational Burden Results In Increased Overall Survival Compared To Estimates From Targeted Gene Panels CI
05-08 Caris Life Sciences Submits Application for Molecular Profiling Test in New York State MT
05-08 Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization CI
05-07 Caris Life Sciences, Inc., Q1 2026 Earnings Call, May 07, 2026
05-07 Caris Life Sciences Reports Q1 Breakeven Results, Revenue Rises; 2026 Guidance Reaffirmed MT
05-07 Earnings Flash (CAI) Caris Life Sciences Posts Q1 EPS $0.0, vs. FactSet Est of -$0.02 MT
05-07 Earnings Flash (CAI) Caris Life Sciences, Inc. Reports Q1 Revenue $216.2M, vs. FactSet Est of $209.4M MT
05-07 Caris Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-05 Caris Life Sciences Launches Caris MI Clarity, The First And Only AI-Powered Test To Predict Both Early And Late Distant Recurrence Risk In Breast Cancer At The Time Of Diagnosis CI
05-04 Caris Life Sciences receives MolDX approval for Caris ChromoSeq, advancing access to comprehensive genomic profiling for myeloid malignancies RE
05-04 Caris Life Sciences Receives MolDX Approval For Caris ChromoSeq CI
1 day-10.53%
1 week-21.17%
Current month-20.63%
1 month-21.17%
3 months-26.87%
6 months-37.94%
Current year-44.11%
1 week 14.89
Extreme 14.89
20.03
1 month 14.89
Extreme 14.89
22.16
Current year 14.89
Extreme 14.89
29.32
1 year 14.89
Extreme 14.89
42.5
3 years 14.89
Extreme 14.89
42.5
5 years 14.89
Extreme 14.89
42.5
10 years 14.89
Extreme 14.89
42.5
Manager TitleAgeSince
Chief Executive Officer 70 31/12/2007
Director of Finance/CFO 45 31/01/2023
President 50 31/10/2016
Director TitleAgeSince
Chairman 70 31/12/2007
Director/Board Member 60 31/12/2007
Director/Board Member 78 31/12/2009
Change 5d. change 1-year change 3-years change Capi.($)
-10.68%-21.17% - - 4.74B
-3.51%+5.72%+135.80%+249.68% 13.25B
+0.75%+4.57%-36.98%-24.31% 10.21B
+1.61%+13.40%+23.75%-1.52% 6.27B
+0.41%+2.72%-6.86%-6.70% 5.73B
+2.02%+1.50%+93.26%+86.97% 4.6B
+2.99%+11.93%-27.18%-33.02% 4.24B
-0.89%+3.55%-11.80%-39.52% 2.92B
-1.22%-8.69%+115.18%-61.41% 2.66B
-3.34%-5.99%+9.40%+36.40% 1.63B
Average -1.12%+3.24%+32.73%+22.95% 5.62B
Weighted average by Cap. -1.14%+5.55%+41.39%+59.28%

Financials

2026 *2027 *
Net sales 1B 857M 786M 744M 1.38B 96.18B 1.39B 9.36B 3.65B 45.62B 3.77B 3.69B 159B 1.21B 1.03B 946M 895M 1.66B 116B 1.67B 11.26B 4.39B 54.89B 4.54B 4.44B 191B
Net income 36.91M 31.48M 28.87M 27.33M 50.64M 3.53B 51.13M 344M 134M 1.68B 138M 136M 5.82B 103M 88.13M 80.83M 76.51M 142M 9.89B 143M 963M 375M 4.69B 388M 380M 16.3B
Net Debt -480M -410M -376M -356M -659M -45.99B -666M -4.48B -1.74B -21.81B -1.8B -1.76B -75.79B -699M -597M -547M -518M -960M -66.94B -969M -6.52B -2.54B -31.75B -2.62B -2.57B -110B
Logo Caris Life Sciences, Inc.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Employees
1,846
Date Price Change Volume
13/05/26 14.91 $ -11.04% 1,037,419
12/05/26 16.76 $ +5.14% 3,278,672
11/05/26 15.94 $ -1.30% 3,256,055
08/05/26 16.15 $ -18.60% 8,874,447
07/05/26 19.84 $ +3.71% 3,377,877
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
16.76USD
Average target price
28.00USD
Spread / Average Target
+67.06%

Quarterly revenue - Rate of surprise